Data from Phase 2 Study of Knopp Biosciences's Dexpramipexole in ALS Published in Nature Medicine
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today announced the publication in Nature Medicine of comprehensive results from the Phase 2 study of dexpramipexole, a small-molecule modulator of mitochondrial bioenergetics, in people with amyotrophic lateral sclerosis (ALS). Dexpramipexole is currently in Phase 3 development under an exclusive worldwide license with Biogen Idec.